ServiceUpdated on 14 August 2025
Phase I clinical trials
About
Our Phase I unit offers a fully integrated environment for early-stage clinical research — bringing together clinical facility, bioanalytical laboratory, and data management under one roof. This streamlined setup shortens timelines, reduces risks, and ensures seamless coordination from study design to final report.
We conduct a wide range of Phase I studies, tailored to your compound’s development needs, including:
✓ First-In-Human (FIH) Studies — Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD)
✓ Food-Effect Studies
✓ Dose Escalation Studies
✓ Drug-Drug Interaction Studies
✓ Bioavailability / Bioequivalence (BA/BE) Studies
✓ Steady-State Studies
✓ Biosimilarity Studies
With all processes — from protocol creation to archiving — handled on-site, we provide unmatched oversight and quality assurance at every stage.
Type
- Others
Applies to
- Pharmaceutical industry
Attached files
Organisation
Similar opportunities
Expertise
ADVANCING PROTEIN DEGRADERS PROTACS or MOLECULAR GLUES
Constantin TAMVAKOPOULOS
Research Director Pharmacology, Center of Clinical, Experimental Surgery & Translational Research, at Pharmacolgy Tamvakopoulos Lab
Athens, Greece
Service
- Consulting
- Development
- Health innovation
- Laboratory industry
- Pharmaceutical industry
Kseniya Tymko
Business Development Director at Pharmbiotest Poland Ltd
Grudziadz, Poland
Expertise
Consultation in drug discovery/drug development activities
Constantin TAMVAKOPOULOS
Research Director Pharmacology, Center of Clinical, Experimental Surgery & Translational Research, at Pharmacolgy Tamvakopoulos Lab
Athens, Greece